Download PDF
Nuklearmedizin
DOI: 10.1055/a-2311-5679
Case Report

Peculiar Pattern of Response Following [225Ac]Ac-PSMA Therapy: A Case Report with ‘PSA Pseudoregression’ Response Pattern

Besonderes Reaktionsmuster nach [225Ac]Ac-PSMA-Therapie: Ein Fallbericht mit „PSA-Pseudoregression“-Reaktionsmuster
Akram Al-Ibraheem
1   Nuclear Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Jordan
2   School of Medicine, The University of Jordan, Al-Jubeiha, Jordan
,
Feras Istatieh
1   Nuclear Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Jordan
,
Ahmed Saad Abdlkadir
1   Nuclear Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Jordan
,
Alaa' Abufara
3   Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Jordan
,
Baha Sharaf
3   Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Jordan
,
Ramiz Abu-Hijlih
4   Radiation Oncology, King Hussein Cancer Center (KHCC), Al-Jubeiha, Jordan
,
Nabeela Al-Hajaj
1   Nuclear Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Jordan
,
Samer Salah
3   Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Jordan
› Author Affiliations
› Further Information
    Permissions and Reprints

Keywords

Prostate cancer - mCRPC - PSMA - Actinium-225 - Pseudoregression - Unusual Pattern


Publication History

Received: 24 January 2024

Accepted after revision: 22 April 2024

Article published online:
17 May 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Al-Ibraheem A. Theranostics in Developing Countries: Addressing Challenges and Potentials from Training to Practice. World J Nucl Med 2023; 22 (03) 171-173 DOI: 10.1055/s-0043-1774733. (PMID: 37854085)
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Cerci JJ, Fanti S, Lobato EE. et al. Diagnostic performance and clinical impact of 68Ga-PSMA-11 PET/CT imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA Study). J Nucl Med 2022; 63 (02) 240-247
    CrossrefPubMedGoogle Scholar
  • 3 Hennrich U, Eder M. 177Lu] Lu-PSMA-617 (PluvictoTM. Pharmaceuticals 2022; 15 (10) 1292 DOI: 10.3390/ph15101292. (PMID: 36297404)
    CrossrefPubMedGoogle Scholar
  • 4 Delker A, Fendler WP, Kratochwil C. et al. Dosimetry for 177 Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 42-51 DOI: 10.1007/s00259-015-3174-7. (PMID: 26318602)
    CrossrefPubMedGoogle Scholar
  • 5 Al-Ibraheem A, Scott AM. 161Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer. Nucl Med Mol Imaging 2023; 1-4
    PubMedGoogle Scholar
  • 6 Satapathy S, Sood A, Das CK. et al. Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—A systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2021; 24 (03) 880-890
    CrossrefPubMedGoogle Scholar
  • 7 Manafi-Farid R, Harsini S, Saidi B. et al. Factors predicting biochemical response and survival benefits following radioligand therapy with [177 Lu] Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. Eur J Nucl Med Mol Imaging 2021; 1-14
    PubMedGoogle Scholar
  • 8 Ahmed ME, Lee MS, Mahmoud AM. et al. Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis 2023; 1-5
    PubMedGoogle Scholar
  • 9 Lehner K, Ahmed ME, Bole R. et al. Effect of early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting on cancer-specific survival in metastatic castrate-resistant prostate cancer. American Society of Clinical Oncology 2023; DOI: 10.1200/JCO.2023.41.6_suppl.189.
    CrossrefGoogle Scholar
  • 10 Kostos L, Buteau JP, Hofman MS. et al. Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2023;15. . DOI: 10.1177/17588359231179309. eCollection 2023.
    CrossrefGoogle Scholar
  • 11 Yordanova A, Linden P, Hauser S. et al. The value of tumor markers in men with metastatic prostate cancer undergoing [177Lu] Lu-PSMA therapy. The Prostate 2020; 80 (01) 17-27
    CrossrefPubMedGoogle Scholar
  • 12 Poteska R, Rahbar K, Semjonow A. et al. The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide. BMC cancer 2022; 22 (01) 1-11
    CrossrefPubMedGoogle Scholar
  • 13 Vatsa R, Sood A, Vadi SK. et al. 225Ac-PSMA-617 radioligand posttherapy imaging in metastatic castrate-resistant prostate cancer patient using 3 photopeaks. Clin Nucl Med 2020; 45 (06) 437-438 DOI: 10.1097/RLU.0000000000003031. (PMID: 32366786)
    CrossrefPubMedGoogle Scholar
  • 14 Araujo JC, Trudel GC, Saad F. et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 2013; 14 (13) 1307-1316
    CrossrefPubMedGoogle Scholar
  • 15 Bryce A, Alumkal J, Armstrong A. et al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis 2017; 20 (02) 221-227
    CrossrefPubMedGoogle Scholar
  • 16 Zisser L, Yu J, Oszwald A. et al. Response to [177Lu] Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases. Nucl Med Commun 2022; 43 (11) 1113
    CrossrefPubMedGoogle Scholar